Skylands Capital LLC cut its stake in Celgene Corporation (NASDAQ:CELG) by 1.6% during the second quarter, Holdings Channel reports. The firm owned 45,200 shares of the biopharmaceutical company’s stock after selling 750 shares during the period. Celgene Corporation makes up about 0.8% of Skylands Capital LLC’s holdings, making the stock its 29th largest position. Skylands Capital LLC’s holdings in Celgene Corporation were worth $5,870,000 at the end of the most recent quarter.

Other large investors also recently added to or reduced their stakes in the company. Diversified Trust Co increased its stake in Celgene Corporation by 0.4% in the first quarter. Diversified Trust Co now owns 2,342 shares of the biopharmaceutical company’s stock valued at $291,000 after buying an additional 9 shares during the period. Sowell Financial Services LLC increased its stake in Celgene Corporation by 0.5% in the first quarter. Sowell Financial Services LLC now owns 2,454 shares of the biopharmaceutical company’s stock valued at $289,000 after buying an additional 13 shares during the period. South Texas Money Management Ltd. increased its stake in Celgene Corporation by 0.6% in the first quarter. South Texas Money Management Ltd. now owns 2,453 shares of the biopharmaceutical company’s stock valued at $305,000 after buying an additional 15 shares during the period. Flagship Harbor Advisors LLC increased its stake in Celgene Corporation by 0.9% in the first quarter. Flagship Harbor Advisors LLC now owns 2,054 shares of the biopharmaceutical company’s stock valued at $253,000 after buying an additional 18 shares during the period. Finally, Keel Point LLC increased its stake in Celgene Corporation by 0.9% in the first quarter. Keel Point LLC now owns 3,103 shares of the biopharmaceutical company’s stock valued at $386,000 after buying an additional 28 shares during the period. 78.41% of the stock is currently owned by institutional investors and hedge funds.

Celgene Corporation (NASDAQ:CELG) traded up 0.18% during trading on Friday, hitting $130.61. The stock had a trading volume of 2,735,623 shares. The firm’s 50-day moving average price is $134.14 and its 200-day moving average price is $124.30. Celgene Corporation has a 52-week low of $96.93 and a 52-week high of $139.00. The company has a market cap of $102.18 billion, a price-to-earnings ratio of 40.45 and a beta of 1.89.

Celgene Corporation (NASDAQ:CELG) last released its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported $1.82 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.61 by $0.21. The business had revenue of $3.27 billion during the quarter, compared to analyst estimates of $3.23 billion. Celgene Corporation had a return on equity of 68.51% and a net margin of 21.35%. The company’s revenue was up 18.7% on a year-over-year basis. During the same quarter last year, the business posted $1.44 EPS. Analysts predict that Celgene Corporation will post $7.32 EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This report was first reported by Watch List News and is the property of of Watch List News. If you are viewing this report on another domain, it was copied illegally and reposted in violation of U.S. & international copyright law. The correct version of this report can be accessed at https://www.watchlistnews.com/skylands-capital-llc-has-5-87-million-stake-in-celgene-corporation-nasdaqcelg/1479680.html.

Several equities research analysts have commented on the company. Jefferies Group LLC set a $154.00 target price on Celgene Corporation and gave the stock a “buy” rating in a report on Saturday, May 13th. BTIG Research downgraded Celgene Corporation from a “buy” rating to a “neutral” rating and boosted their target price for the stock from $96.93 to $131.70 in a report on Friday, June 30th. Vetr raised Celgene Corporation from a “buy” rating to a “strong-buy” rating and set a $148.32 target price on the stock in a report on Thursday. Robert W. Baird reissued an “outperform” rating and issued a $162.00 target price on shares of Celgene Corporation in a report on Monday, May 22nd. Finally, SunTrust Banks, Inc. set a $150.00 target price on Celgene Corporation and gave the stock a “buy” rating in a report on Thursday, July 6th. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating, twenty-two have given a buy rating and one has given a strong buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $147.00.

In related news, insider Robert J. Hugin sold 175,970 shares of Celgene Corporation stock in a transaction dated Thursday, June 22nd. The stock was sold at an average price of $134.14, for a total value of $23,604,615.80. Following the completion of the transaction, the insider now owns 1,033,909 shares in the company, valued at approximately $138,688,553.26. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Rupert Vessey sold 4,785 shares of Celgene Corporation stock in a transaction dated Thursday, June 15th. The shares were sold at an average price of $120.18, for a total value of $575,061.30. Following the completion of the transaction, the insider now owns 4,004 shares of the company’s stock, valued at approximately $481,200.72. The disclosure for this sale can be found here. Insiders have sold a total of 235,255 shares of company stock valued at $31,377,042 in the last quarter. Company insiders own 0.95% of the company’s stock.

Celgene Corporation Company Profile

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Corporation (NASDAQ:CELG).

Institutional Ownership by Quarter for Celgene Corporation (NASDAQ:CELG)

Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.